Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for rare genetic disorders, particularly those that lead to life-threatening metabolic conditions. The company’s primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for the treatment of obesity related to pro-opiomelanocortin (POMC) and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, it is in Phase II trials for various other genetic obesity disorders. Rhythm Pharmaceuticals is also advancing RM-853, an orally available ghrelin o-acyltransferase inhibitor in preclinical development aimed at addressing Prader-Willi syndrome. Founded in 2008 and based in Boston, Massachusetts, the company previously operated under the name Rhythm Metabolic, Inc. and rebranded in October 2015.
Xinvento
Acquisition in 2023
Xinvento focuses on developing treatments for congenital hyperinsulinism, a condition that leads to excessive insulin secretion. The company aims to improve the lives of patients affected by this disorder and related illnesses by researching and creating therapeutics that regulate insulin levels. By addressing this critical health issue, Xinvento helps prevent severe complications such as seizures, coma, permanent brain damage, and even death.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.